Zist Arvand Pharmed Company (DARVAND) income statement
Operating revenue through to net profit and earnings per share
- Ticker
- DARVAND
- Industry
- Pharmaceuticals
- Market
- Tehran Stock Exchange
Latest periods
| Item | To 1405/06/31 | To 1404/06/31 |
|---|---|---|
| Operating revenue | 26,601,406 | 8,429,950 |
| Cost of operating revenue | -6,711,668 | -2,874,386 |
| Gross profit (loss) | 19,889,738 | 5,555,564 |
| Selling, general and administrative expenses | -5,007,118 | -1,664,352 |
| Other income | 4,394 | 11 |
| Other expenses | -609,157 | -308,551 |
| Operating profit (loss) | 14,277,857 | 3,582,672 |
| Finance costs | -2,721,674 | -655,687 |
| Other non-operating income and expenses | -3,183 | 10,944 |
| Profit (loss) from continuing operations before tax | 11,553,000 | 2,937,929 |
| Current year tax | -1,372,149 | -379,310 |
| Net profit (loss) from continuing operations | 10,180,851 | 2,558,619 |
| Net profit (loss) | 10,180,851 | 2,558,619 |
| Net earnings (loss) per share, rials | 849 rials | 512 rials |
| Capital | 12,000,000 | 5,000,000 |
Reporting periods
11 periods are on file for this report, from the period ending 1400/12/29 to the period ending 1405/06/31.